饮食干预联合硫普罗宁治疗酒精肝临床研究

摘要

目的：研究饮食干预联合硫普罗宁治疗对于酒精肝治疗的安全性和有效性。方法选取该院门诊自2010年7月—2012年7月收治的酒精肝患者120例，随机分为观察组和对照组，其中观察组60例以饮食干预联合硫普罗宁进行治疗，而对照组60例以单纯的硫普罗宁进行治疗，观察两组治疗结果。结果观察组患者ALT、AST、γ-GT指标分别为（60.3±48.1） U/L、（78.2±42.2） U/L、（71.4±31.3） U/L，明显低于对照组患者 ALT、AST、γ-GT 的（71.2±50.3） U/L、（91.3±50.4） U/L、（80.2±32.1） U/L，差异具有统计学意义（P<0.05）；观察组患者TBIL为（17.6±14.7）μmol/L与对照组患者TBIL的（17.8±15.5）μmol/L差别不显著，差异无统计学意义（P>0.05）。经过患者的临床治疗，以评分标准进行评定，观察组患者评分的优良率为96.7%明显优于对照组的患者优良率85.0%，差异有统计学意义（P<0.05）。结论饮食干预联合硫普罗宁对于酒精肝的治疗效果显著，适用于我国患有酒精肝的患者。%Objective To observe the effects of diet intervention combined with tiopronin on treatment of alcoholic liver disease Methods 120 patients with alcoholic liver disease were received in our clinic service, and were randomly divided into treatment group and control group. Treatment group (60 patients) were given intervention and tiopronin, and control group (60 patients) was treated with tiopronin. The symptoms and liver function were tested. Results ALT, AST andγ-GT in treatment group(60.3±48.1 U/L, 78.2±42.2 U/L and 31.3 U/L, respectively) were obviously lower than control group (71.2±50.3 U/L, 91.3±50.4 U/L, 80.2±32.1 U/L , P<0.05). TBIL in treatment group(17.6±14.7μmol/L) was lower than control group(17.8±15.5μmol/L), but the difference was not significant (P>0.05).The fineness rate measured by efficiency score in treatment group was better than the fineness rate in control group (96.7%VS. 85.0%, P<0.05). Conclusion The curative effect diet intervention combined with tiopronin is good for al-coholic liver disease treatment and worthy to popularize in Chinese patients.